^
Association details:
| Biomarker: | ROS1 fusion + ROS1 G2032R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Augtyro (repotrectinib) (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, Trk inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract PR003: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
Published date:
12/01/2023
Excerpt:
Pts with ROS1+ NSCLC were assigned to 4 cohorts by treatment history: TKI-naïve, 1 TKI and no chemo, 1 TKI and 1 platinum-based chemo, and 2 TKIs and no chemo. Repotrectinib RP2D was 160 mg once daily for 14 days, then 160 mg twice daily....In pts with TKI-pretreated ROS1 G2032R NSCLC (n=17), cORR was 59% (33–82).
DOI:
https://doi.org/10.1158/1535-7163.TARG-23-PR003
Trial ID:
Source:
Title:
Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)
Published date:
10/28/2022
Excerpt:
We report updated results in TKI-naïve and -pretreated patients with advanced, ROS1 fusion-positive (ROS1+) NSCLCs....Repotrectinib achieves durable activity, including intracranial responses, in TKI-naïve and TKI-pretreated patients with ROS1+ advanced NSCLC, and those with ROS1 G2032R.
DOI:
https://doi.org/10.1016/S0959-8049(22)00812-7
Trial ID:
